Thermo Fisher Scientific's TSG Series Freezers and Sample Preparation Refrigerators are designed for laboratories that need efficient and sustainable cold storage solutions.

Revvity, Inc. (NYSE: RVTY), announced the launch of EUROIMMUN’s CE-marked Anti-Measles Virus ELISA 2.0 (IgG) to support the diagnosis of a measles virus infection or to determine the immune status against measles virus.

BIOHIT OYJ is excited to announce the launch of the BIOHIT FAEX Sample System, a stool sample collection and handling solution that can be seamlessly incorporated into any diagnostic workflow.

BIOHIT HealthCare is pleased to announce that a clinical study conducted by Homerton University Hospital NHS Foundation Trust, London, has confirmed the diagnostic accuracy of GastroPanel in identifying gastric cancer risk in patients.

Thermo Fisher Scientific has received 510(k) clearance from the U.S. Food & Drug Administration (FDA) for the Applied Biosystems™ TaqPath™ COVID-19, Flu A, Flu B, RSV Select Panel.

PacBio (NASDAQ: PACB), announced a significant publication from Radboud University Medical Center (Radboudumc) and its research partners in the American Journal of Human Genetics.

Spear Bio Inc., announced that its pTau 217 blood test has been granted Breakthrough Device Designation by the U.S. Food and Drug Administration (FDA).

Revvity, Inc. announced a strategic agreement to commercialize an in vitro diagnostic (IVD) workflow solution for neonatal sequencing, co-developed with Element Biosciences, Inc.

Revvity, Inc. (NYSE: RVTY), announced that it received 510(k) clearance from the U.S. Food and Drug Administration (FDA) for EUROIMMUN’s automated chemiluminescence-based immunoassay (ChLIA) test for free testosterone.

Bio-Rad leads investment to support the launch of ColoSense®, a non-invasive colorectal cancer screening test, and advance diagnostic innovations for inflammatory bowel disease.